Recruiting

Testing a new drug combination for blood cancer that didn't respond to prior treatment

Plain-English translation of NCT04905810 on ClinicalTrials.gov ↗ · Source last updated May 2024 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing combined with a different hypomethylating agent (either or ) for people with acute myeloid leukemia whose cancer did not respond to hypomethylating agents in the past. The study wants to see if switching to an alternative medication in this drug combination class, paired with , can help patients whose cancer has become resistant to their previous treatment.

Some people with acute myeloid leukemia stop responding to hypomethylating agent medications, and their cancer continues to grow or comes back. This trial exists to find out whether using a different hypomethylating agent alongside might work better for these patients who have exhausted their initial treatment options.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been newly diagnosed with acute myeloid leukemia and are eligible to receive venetoclax with a hypomethylating agent
you previously received hypomethylating agents (azacitidine or decitabine) for a related blood disorder and your cancer did not respond or came back
you either are 75 or older, or are between 18–74 with at least one significant health condition (such as heart disease, lung disease, or kidney problems) that makes intensive chemotherapy unsuitable
you have white blood cell counts of at least 25,000/mm³ at the time you would start treatment

You likely don't qualify if…

you have severe liver disease or kidney disease that falls outside the study's acceptable range
you are pregnant or planning to become pregnant during or within 90 days after treatment
you have active graft-versus-host disease or require ongoing immune-suppressing medication from a previous bone marrow transplant
you have serious heart, lung, liver, or kidney problems that are too severe for this treatment, unless your doctor has reviewed your case with the study chair

What participation looks like

You would take the medication in 28-day cycles, receiving infusions or injections of either or on specific days of each cycle, along with a daily oral medication () that you take by mouth every day for the full 28 days. The cycles repeat as long as your cancer responds and you tolerate the treatment well. You would likely have regular blood tests and doctor visits to monitor how you're responding and check for side effects.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(4 sites)

United States

UCSF-Fresno, Clovis, California

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma